Skip to main content
SpringerLink
Log in

TGF-β, Smads and Cervical Cancer

  • Chapter
Transforming Growth Factor-β in Cancer Therapy, Volume II

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Cervical cancer is one of the most frequent cancers affecting women worldwide. Infection with human papilloma virus aided by several cofactors is causally related to cervical carcinogenesis. HPV infection is known to influence TGF-β signaling and TGF-β may stimulate normal cervical remodeling and limit HPV-immortalized cervical cell progression. Loss of heterozygosity of chromosomes that harbor Smads and/or TGF-β receptors reported in human cervical cancer suggests that inactivation of their genes may play a role in the progression of cervical carcinoma. Cervical cancer is associated with enhanced production of TGF-β, repression or mutation of TGF-β transmembrane receptors, or loss of expression and/or mutations in Smads. Therapeutic approaches should aim to inhibit the TGF-β-induced invasive phenotype, but also to retain its growth-inhibitory and apoptosis-inducing effects. Interrelationships between TGF-β signaling and HPV oncoproteins as well as latest developments on the molecular alterations in human cervical cancer associated with TGF-β signaling are described in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003;3:807–821.

    Article  CAS  PubMed  Google Scholar 

  2. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004;29: 265–273.

    Article  PubMed  Google Scholar 

  3. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massagué J. The TGF beta receptor activation process: an inhibitor-to substrate-binding switch. Mol Cell 2001;8:671–682.

    Article  CAS  PubMed  Google Scholar 

  4. Mehra A, Wrana JL. TGF-beta and the Smad signal transduction pathway. Biochem Cell Biol 2002;80:605–622.

    Article  CAS  PubMed  Google Scholar 

  5. Liu F, Pouponnot C, Massagué J. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev 1997;11:3157–3167.

    Article  CAS  PubMed  Google Scholar 

  6. Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor beta signal transduction. J Leukoc Biol 2002;71:731–740.

    CAS  PubMed  Google Scholar 

  7. Sanchez-Capelo A. Dual role for TGF-beta1 in apoptosis. Cytokine Growth Factor Rev 2005;16:15–34.

    Article  CAS  PubMed  Google Scholar 

  8. Narayan S, Thangasamy T, Balusu R. Transforming growth factor-beta receptor signaling in cancer. Front Biosci 2005;10:1135–1145.

    Article  CAS  PubMed  Google Scholar 

  9. Reynisdottir I, Polyak K, Iavarone A, Massagué J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995;9:1831–1845.

    Article  CAS  PubMed  Google Scholar 

  10. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257–261.

    Article  CAS  PubMed  Google Scholar 

  11. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995;92:5545–5549.

    Article  CAS  PubMed  Google Scholar 

  12. Massagué J. G1 cell-cycle control and cancer. Nature 2004;432:298–306.

    Article  PubMed  Google Scholar 

  13. Cain JM, Howett MK. Preventing cervical cancer. Science 2000;288:1753–1755.

    Article  CAS  PubMed  Google Scholar 

  14. Schoell WM, Janicek MF, Mirhashemi R. Epidemiology and biology of cervical cancer. Semin Surg Oncol 1999;16:203–211.

    Article  CAS  PubMed  Google Scholar 

  15. zur Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55–F78.

    PubMed  Google Scholar 

  16. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1–17.

    Article  CAS  PubMed  Google Scholar 

  17. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690–698.

    Article  PubMed  Google Scholar 

  18. Chakrabarti O, Krishna S. Molecular interactions of ‘high risk’ human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression. J Biosci 2003;28:337–348.

    Article  CAS  PubMed  Google Scholar 

  19. Lee DK, Kim BC, Kim IY, Cho EA, Satterwhite DJ, Kim SJ. The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signaling by blocking binding of the Smad complex to its target sequence. J Biol Chem 2002;277:38,557–38,564.

    Article  CAS  PubMed  Google Scholar 

  20. Favre-Bonvin A, Reynaud C, Kretz-Remy C, Jalinot P. Human papillomavirus type 18 E6 protein binds the cellular PDZ protein TIP-2/GIPC, which is involved in transforming growth factor beta signaling and triggers its degradation by the proteasome. J Virol 2005;79:4229–4237.

    Article  CAS  PubMed  Google Scholar 

  21. Moses HL. TGF-beta regulation of epithelial cell proliferation. Mol Reprod Dev 1992;32:179–184.

    Article  CAS  PubMed  Google Scholar 

  22. Creek KE, Geslani G, Batova A, Pirisi L. Progressive loss of sensitivity to growth control by retinoic acid and transforming growth factor-beta at late stages of human papillomavirus type 16-initiated transformation of human keratinocytes. Adv Exp Med Biol 1995;375:117–135.

    CAS  PubMed  Google Scholar 

  23. Nees M, Geoghegan JM, Munson P, et al. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. Cancer Res 2000;60:4289–4298.

    CAS  PubMed  Google Scholar 

  24. Baldwin A, Pirisi L, Creek KE. NFI-Ski interactions mediate transforming growth factor beta modulation of human papillomavirus type 16 early gene expression. J Virol 2004;78:3953–3964.

    Article  CAS  PubMed  Google Scholar 

  25. Shier MK, Neely EB, Ward MG, Meyers C, Howett MK. Transforming growth factor beta 1 (TGF beta 1) down-regulates expression and function of proliferation-inducing molecules in HPV-transformed cells. Anticancer Res 1999;19:4977–4982.

    CAS  PubMed  Google Scholar 

  26. Shier MK, Neely EB, Ward MG, et al. Correlation of TGF beta 1 overexpression with down-regulation of proliferation-inducing molecules in HPV-11 transformed human tissue xenografts. Anticancer Res 1999;19:4969–4976.

    CAS  PubMed  Google Scholar 

  27. Rorke EA, Jacobberger JW. Transforming growth factor-beta 1 (TGF beta 1) enhances apoptosis in human papillomavirus type 16-immortalized human ectocervical epithelial cells. Exp Cell Res 1995; 216:65–72.

    Article  CAS  PubMed  Google Scholar 

  28. Kim JW, Kim HS, Kim IK, et al. Transforming growth factor-beta 1 induces apoptosis through down-regulation of c-myc gene and overexpression of p27Kip1 protein in cervical carcinoma. Gynecol Oncol 1998;69:230–236.

    Article  CAS  PubMed  Google Scholar 

  29. De Geest K, Bergman CA, Turyk ME, Frank BS, Wilbanks GD. Differential response of cervical intraepithelial and cervical carcinoma cell lines to transforming growth factor-beta 1. Gynecol Oncol 1994;55:376–385.

    Article  CAS  PubMed  Google Scholar 

  30. Braun L, Durst M, Mikumo R, Gruppuso P. Differential response of nontumorigenic and tumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor beta 1. Cancer Res 1990;50:7324–7332.

    CAS  PubMed  Google Scholar 

  31. Braun L, Durst M, Mikumo R, Crowley A, Robinson M. Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor-beta: implications for the control of papillomavirus infection. Mol Carcinog 1992;6:100–111.

    Article  CAS  PubMed  Google Scholar 

  32. Ozbun MA, Meyers C. Transforming growth factor betal induces differentiation in human papillomavirus-positive keratinocytes. J Virol 1996;70:5437–5446.

    CAS  PubMed  Google Scholar 

  33. Ho L, Terry G, Mansell B, Butler B, Singer A. Detection of DNA and E7 transcripts of human papillomavirus types 16, 18, 31, and 33, TGF beta and GM-CSF transcripts in cervical cancers and precancers. Arch Virol 1994;139:79–85.

    Article  CAS  PubMed  Google Scholar 

  34. Jacobberger JW, Sizemore N, Gorodeski G, Rorke EA. Transforming growth factor beta regulation of epidermal growth factor receptor in ectocervical epithelial cells. Exp Cell Res 1995;220:390–396.

    Article  CAS  PubMed  Google Scholar 

  35. Woodworth CD, Chung J, McMullin E, Plowman GD, Simpson S, Iglesias M. Transforming growth factor beta 1 supports autonomous growth of human papillomavirus-immortalized cervical keratinocytes under conditions promoting squamous differentiation. Cell Growth Differ 1996;7:811–820.

    CAS  PubMed  Google Scholar 

  36. Rorke EA, Zhang D, Choo CK, Eckert RL, Jacobberger JW. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21 (WAF-1) expression. Exp Cell Res 2000;259:149–157.

    Article  CAS  PubMed  Google Scholar 

  37. Arany I, Rady P, Tyring SK. Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway. Antiviral Res 1994;23:131–141.

    Article  CAS  PubMed  Google Scholar 

  38. Maliekal TT, Anto RJ, Karunagaran D. Differential activation of Smads in HeLa and SiHa cells that differ in their response to transforming growth factor-beta. J Biol Chem 2004;279:36,287–36,292.

    Article  CAS  PubMed  Google Scholar 

  39. Wrana JL, Attisano L, Carcamo J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992;71:1003–1014.

    Article  CAS  PubMed  Google Scholar 

  40. Westerhausen DR, Jr., Hopkins WE, Billadello JJ. Multiple transforming growth factor-beta-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J Biol Chem 1991;266:1092–1100.

    CAS  PubMed  Google Scholar 

  41. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem 1991;266:23,048–23,052.

    CAS  PubMed  Google Scholar 

  42. Yi JY, Hur KC, Lee E, Jin YJ, Arteaga CL, Son YS. TGFbeta1-mediated epithelial to mesenchymal transition is accompanied by invasion in the SiHa cell line. Eur J Cell Biol 2002;81:457–468.

    Article  CAS  PubMed  Google Scholar 

  43. Kang SH, Won K, Chung HW, et al. Genetic integrity of transforming growth factor beta (TGF-beta) receptors in cervical carcinoma cell lines: loss of growth sensitivity but conserved transcriptional response to TGF-beta. Int J Cancer 1998;77:620–625.

    Article  CAS  PubMed  Google Scholar 

  44. Lee S, Cho YS, Shim C, et al. Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line. Int J Cancer 2001;94:500–507.

    Article  CAS  PubMed  Google Scholar 

  45. Suganuma T, Kawabata M, Ohshima T, Ikeda MA. Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator. Proc Natl Acad Sci USA 2002;99:13,073–13,078.

    Article  CAS  PubMed  Google Scholar 

  46. Maliekal TT, Antony ML, Nair A, Paulmurugan R, Karunagaran D. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene 2003;22: 4889–4897.

    Article  CAS  PubMed  Google Scholar 

  47. James GK, Kalousek DK, Auersperg N. Karyotypic analysis of two related cervical carcinoma cell lines that contain human papillomavirus type 18 DNA and express divergent differentiation. Cancer Genet Cytogenet 1989;38:53–60.

    Article  CAS  PubMed  Google Scholar 

  48. Yan Z, Winawer S, Friedman E. Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem 1994;269:13,231–13,237.

    CAS  PubMed  Google Scholar 

  49. Baldus SE, Schwarz E, Lohrey C, et al. Smad4 deficiency in cervical carcinoma cells. Oncogene 2005;24:810–819.

    Article  CAS  PubMed  Google Scholar 

  50. Kloth JN, Fleuren GJ, Oosting J, et al. Substantial changes in gene expression of Wnt, MAPK and TNFα pathways induced by TGF-β1 in cervical cancer cell lines. Carcinogenesis 2005;26:1493–1502.

    Article  CAS  PubMed  Google Scholar 

  51. Dong C, Li Z, Alvarez R, Jr., Feng XH, Glodschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 2000;5:27–34.

    Article  CAS  PubMed  Google Scholar 

  52. Choi HH, Jong HS, Hyun Song S, You Kim T, Kyeong Kim N, Bang YJ. p130 mediates TGF-beta-induced cell-cycle arrest in Rb mutant HT-3 cells. Gynecol Oncol 2002;86:184–189.

    Article  CAS  PubMed  Google Scholar 

  53. Agarwal C, Hembree JR, Rorke EA, Eckert RL. Transforming growth factor beta 1 regulation of metalloproteinase production in cultured human cervical epithelial cells. Cancer Res 1994;54:943–949.

    CAS  PubMed  Google Scholar 

  54. Yoneda K, Yokoyama T, Yamamoto T, Hatabe T, Osaki T. p53 gene mutations and p21 protein expression induced independently of p53, by TGF-beta and gamma-rays in squamous cell carcinoma cells. Eur J Cancer 1999;35:278–283.

    Article  CAS  PubMed  Google Scholar 

  55. Rakowicz-Szulczynska EM, McIntosh DG, Smith M. Growth factor-mediated mechanisms of nicotine-dependent carcinogenesis. Carcinogenesis 1994;15:1839–1846.

    Article  CAS  PubMed  Google Scholar 

  56. Masuda S, Kumano K, Shimizu K, et al. Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of coactivator p300. Cancer Sci 2005;96:274–282.

    Article  CAS  PubMed  Google Scholar 

  57. Nuovo GJ. In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines. Int J Cancer 1997;71:1056–1060.

    Article  CAS  PubMed  Google Scholar 

  58. Kim SJ, Wagner S, Liu F, O’Reilly MA, Robbins PD, Green MR. Retinoblastoma gene product activates expression of the human TGF-beta 2 gene through transcription factor ATF-2. Nature 1992;358:331–334.

    Article  CAS  PubMed  Google Scholar 

  59. Hayes S, Chawla A, Corvera S. TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J Cell Biol 2002;158(7):1239–1249.

    Article  CAS  PubMed  Google Scholar 

  60. Janknecht R, Wells NJ, Hunter T. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev 1998;12:2114–2119.

    Article  CAS  PubMed  Google Scholar 

  61. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001;276:38,527–38,535.

    Article  CAS  PubMed  Google Scholar 

  62. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002;277:43,799–43,808.

    Article  CAS  PubMed  Google Scholar 

  63. Lee PS, Chang C, Liu D, Derynck R. Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. J Biol Chem 2003;278:27,853–27,863.

    Article  CAS  PubMed  Google Scholar 

  64. Liang M, Melchior F, Feng XH, Lin X. Regulation of Smad4 sumoylation and transforming growth factor-beta signaling by protein inhibitor of activated STAT1. J Biol Chem 2004;279:22,857–22,865.

    Article  CAS  PubMed  Google Scholar 

  65. Chen HB, Rud JG, Lin K, Xu L. Nuclear targeting of transforming growth factor-beta-activated Smad complexes. J Biol Chem 2005;280:21,329–21,336.

    Article  CAS  PubMed  Google Scholar 

  66. Suzuki C, Murakami G, Fukuchi M, et al. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem 2002;277:39,919–39,925.

    Article  CAS  PubMed  Google Scholar 

  67. Tajima Y, Goto K, Yoshida M, et al. Chromosomal region maintenance 1 (CRM1)-dependent nuclear export of Smad ubiquitin regulatory factor 1 (Smurf1) is essential for negative regulation of transforming growth factor-beta signaling by Smad7. J Biol Chem 2003;278:10,716–10,721.

    Article  CAS  PubMed  Google Scholar 

  68. Denissova NG, Liu F. Repression of endogenous Smad7 by Ski. J Biol Chem 2004;279:28,143–28,148.

    Article  CAS  PubMed  Google Scholar 

  69. Li SL, Kim MS, Cherrick HM, Doniger J, Park NH. Sequential combined tumorigenic effect of HPV-16 and chemical carcinogens. Carcinogenesis 1992;13:1981–1987.

    Article  CAS  PubMed  Google Scholar 

  70. El-Sherif AM, Seth R, Tighe PJ, Jenkins D. Decreased synthesis and expression of TGF-beta1, beta2, and beta3 in epithelium of HPV 16-positive cervical precancer: a study by microdissection, quantitative RT-PCR, and immunocytochemistry. J Pathol 2000;192:494–501.

    Article  CAS  PubMed  Google Scholar 

  71. Xu XC, Mitchell MF, Silva E, Jetten A, Lotan R. Decreased expression of retinoic acid receptors, transforming growth factor beta, involucrin, and cornifin in cervical intraepithelial neoplasia. Clin Cancer Res 1999;5:1503–1508.

    CAS  PubMed  Google Scholar 

  72. Tervahauta A, Syrjanen S, Yliskoski M, Gold LI, Syrjanen K. Expression of transforming growth factor-beta 1 and-beta-2 in human papillomavirus (HPV)-associated lesions of the uterine cervix. Gynecol Oncol 1994;54:349–356.

    Article  CAS  PubMed  Google Scholar 

  73. Comerci JT, Jr., Runowicz CD, Flanders KC, et al. Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer 1996;77:1107–1114.

    Article  PubMed  Google Scholar 

  74. Hazelbag S, Gorter A, Kenter GG, van den Broek L, Fleuren G. Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol 2002;33:1193–1199.

    Article  CAS  PubMed  Google Scholar 

  75. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E, Spandidos DA. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 2005;221:105–118.

    Article  CAS  PubMed  Google Scholar 

  76. Hazelbag S, Kenter GG, Gorter A, Fleuren GJ. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer 2004;112:1020–1028.

    Article  CAS  PubMed  Google Scholar 

  77. Comerci JT, Jr., Runowicz CD, Fields AL, et al. Induction of transforming growth factor beta-1 in cervical intraepithelial neoplasia in vivo after treatment with beta-carotene. Clin Cancer Res 1997; 3:157–160.

    CAS  PubMed  Google Scholar 

  78. Giannini SL, Al-Saleh W, Piron H, et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 1998;113:183–189.

    Article  CAS  PubMed  Google Scholar 

  79. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC. Predominant Th2/Tc2 polarity of tumorinfiltrating lymphocytes in human cervical cancer. J Immunol 2001;167:2972–2978.

    CAS  PubMed  Google Scholar 

  80. Tjiong MY, van der Vange N, ter Schegget JS, Burger MP, ten Kate FW, Out TA. Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine 2001;14:357–360.

    Article  CAS  PubMed  Google Scholar 

  81. Sheu BC, Chiou SH, Lin HH, et al. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res 2005;65:2921–2929.

    Article  CAS  PubMed  Google Scholar 

  82. Hazelbag S; Fleuren GJ, Baelde JJ, Schuuring E, Kenter GG, Gorter A. Cytokine profile of cervical cancer cells. Gynecol Oncol 2001;83:235–243.

    Article  CAS  PubMed  Google Scholar 

  83. Wu HS, Li YF, Chou CI, Yuan CC, Hung MW, Tsai LC. The concentration of serum transforming growth factor beta-1 (TGF-beta1) is decreased in cervical carcinoma patients. Cancer Invest 2002;20:55–59.

    Article  PubMed  Google Scholar 

  84. Moon HS, Kim SC, Ahn JJ, Woo BH. Concentration of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in the serum of patients with cervical cancer: prediction of response. Int J Gynecol Cancer 2000;10:151–156.

    Article  PubMed  Google Scholar 

  85. Chopra V, Dinh TV, Hannigan EV. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 1998;16:152–159.

    Article  CAS  PubMed  Google Scholar 

  86. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 2001;20:133–143.

    Article  CAS  PubMed  Google Scholar 

  87. Mullokandov MR, Kholodilov NG, Atkin NB, Burk RD, Johnson AB, Klinger HP. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 1996;56:197–205.

    CAS  PubMed  Google Scholar 

  88. Kersemaekers AM, Kenter GG, Hermans J, Fleuren GJ, van de Vijver MJ. Allelic loss and prognosis in carcinoma of the uterine cervix. Int J Cancer 1998;79:411–417.

    Article  CAS  PubMed  Google Scholar 

  89. Kersemaekers AM, van de Vijver MJ, Kenter GG, Fleuren GJ. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer 1999;26:346–354.

    Article  CAS  PubMed  Google Scholar 

  90. Dellas A, Torhorst J, Jiang F, et al. Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic hybridization. Cancer Res 1999;59:3475–3479.

    CAS  PubMed  Google Scholar 

  91. Chu TY, Lai JS, Shen CY, Liu HS, Chao CF. Frequent aberration of the transforming growth factor-beta receptor II gene in cell lines but no apparent mutation in pre-invasive and invasive carcinomas of the uterine cervix. Int J Cancer 1999;80:506–510.

    Article  CAS  PubMed  Google Scholar 

  92. Torng PL, Chan WY, Lin CT, Huang SC. Decreased expression of human papillomavirus E2 protein and transforming growth factor-beta1 in human cervical neoplasia as an early marker in carcinogenesis. J Surg Oncol 2003;84:17–23.

    Article  CAS  PubMed  Google Scholar 

  93. Farley J, Gray K, Nycum L, Prentice M, Birrer MJ, Jakowlew SB. Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-beta and a contrasting decrease in p27 (Kip1). Gynecol Oncol 2000;78:113–122.

    Article  CAS  PubMed  Google Scholar 

  94. Hudelist G, Czerwenka K, Singer C, Pischinger K, Kubista E, Manavi M. cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study. Cancer Genet Cytogenet 2005;158:35–42.

    Article  CAS  PubMed  Google Scholar 

  95. Chen T, de Vries EG, Hollema H, et al. Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer 1999;82:43–51.

    Article  CAS  PubMed  Google Scholar 

  96. Li Y, Han B, Li K, Jiao LR, Habib N, Wang H. TGF-beta 1 inhibits HLA-DR and beta 2-microglobulin expression in HeLa cells induced with r-IFN. Transplant Proc 1999;31:2143–2145.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamilnadu, India

    Devarajan Karunagaran PhD

  2. Division of Cancer Biology, Rajiv Gandhi Center for Biotechnology, Thiruvananthapuram, Kerala, India

    Goodwin Jinesh MSc

Authors
  1. Devarajan Karunagaran PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Goodwin Jinesh MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Training Branch, Office of Centers, Training and Resources, National Cancer Institute, Bethesda, MD

    Sonia B. Jakowlew PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Karunagaran, D., Jinesh, G. (2008). TGF-β, Smads and Cervical Cancer. In: Jakowlew, S.B. (eds) Transforming Growth Factor-β in Cancer Therapy, Volume II. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-293-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-293-9_3

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-715-0

  • Online ISBN: 978-1-59745-293-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation